Skip to main content

Research Repository

Advanced Search

Anti-nicastrin monoclonal antibodies elicit pleiotropic anti-tumour pharmacological effects in invasive breast cancer cells

Filipovi?, Aleksandra; Lombardo, Ylenia; Fronato, Monica; Abrahams, Joel; Aboagye, Eric; Nguyen, Quang-De; d�Aqua, Barbara Borda; Ridley, Anne; Green, Andrew; Rahka, Emad; Ellis, Ian; Recchi, Chiara; Przulj, Natasa; Sarajli?, Anida; Alattia, Jean-Rene; Fraering, Patrick; Deonarain, Mahendra; Coombes, R. Charles


Aleksandra Filipovi?

Ylenia Lombardo

Monica Fronato

Joel Abrahams

Eric Aboagye

Quang-De Nguyen

Barbara Borda d�Aqua

Anne Ridley

Professor of Breast Cancer Pathology

Chiara Recchi

Natasa Przulj

Anida Sarajli?

Jean-Rene Alattia

Patrick Fraering

Mahendra Deonarain

R. Charles Coombes


The goal of targeted cancer therapies is to specifically block oncogenic signalling, thus maximising efficacy, while reducing side-effects to patients. The gamma-secretase (GS) complex is an attractive therapeutic target in haematological malignancies and solid tumours with major pharmaceutical activity to identify optimal inhibitors. Within GS, nicastrin (NCSTN) offers an opportunity for therapeutic intervention using blocking monoclonal antibodies (mAbs). Here we explore the role of anti-nicastrin monoclonal antibodies, which we have developed as specific, multi-faceted inhibitors of proliferation and invasive traits of triple-negative breast cancer cells. We use 3D in vitro proliferation and invasion assays as well as an orthotopic and tail vail injection triple-negative breast cancer in vivo xenograft model systems. RNAScope assessed nicastrin in patient samples. Anti-NCSTN mAb clone-2H6 demonstrated a superior anti-tumour efficacy than clone-10C11 and the RO4929097 small molecule GS inhibitor, acting by inhibiting GS enzymatic activity and Notch signalling in vitro and in vivo. Confirming clinical relevance of nicastrin as a target, we report evidence of increased NCSTN mRNA levels by RNA in situ hybridization (RNAScope) in a large cohort of oestrogen receptor negative breast cancers, conferring independent prognostic significance for disease-free survival, in multivariate analysis. We demonstrate here that targeting NCSTN using specific mAbs may represent a novel mode of treatment for invasive triple-negative breast cancer, for which there are few targeted therapeutic options. Furthermore, we propose that measuring NCSTN in patient samples using RNAScope technology may serve as companion diagnostic for anti-NCSTN therapy in the clinic.


Filipović, A., Lombardo, Y., Fronato, M., Abrahams, J., Aboagye, E., Nguyen, Q., …Coombes, R. C. (2014). Anti-nicastrin monoclonal antibodies elicit pleiotropic anti-tumour pharmacological effects in invasive breast cancer cells. Breast Cancer Research and Treatment, 148(2), 455-462.

Journal Article Type Article
Acceptance Date Aug 27, 2014
Online Publication Date Sep 24, 2014
Publication Date Nov 30, 2014
Deposit Date Oct 17, 2018
Publicly Available Date Oct 17, 2018
Journal Breast Cancer Research and Treatment
Print ISSN 0167-6806
Electronic ISSN 1573-7217
Publisher Springer Verlag
Peer Reviewed Peer Reviewed
Volume 148
Issue 2
Pages 455-462
Keywords Nicastrin; Breast cancer; Monoclonal antibodies
Public URL
Publisher URL